loader image


Sibylla’s vision is to treat currently incurable diseases.

We have the ambition of saving human lives and improving the quality of life of the people they love.
Sibylla was born out of research on prion diseases, transmissible neurodegenerative disorders that cause a terrible death in patients. The life-lasting engagement of our academic founders was finding a cure for that.

The objective that drives everybody at Sibylla is precisely the same: to work hard and passionately because one day, a diagnosis of severe disease could be followed by the indication of life-saving therapy. We aim at relieving both the patients with their families and friends and the medical staff from the burden of an incurable verdict.

At Sibylla, we believe in a social engagement that science should never fail. We are engaged in collaborative programs that may help unfortunate patients on large (AMR) or small (pediatric rare diseases) scales regardless of the immediate return.


We revolutionize the Targeted Protein Degradation (TPD) field by unveiling a novel class of folding interfering degraders.

Complexity needs fast adapting innovation. Innovation today must adapt to a world where continuous discoveries set increasingly challenging goals. Innovation requires a change of mindset, where one should not be afraid to walk off the pathway.

At Sibylla, we believe that innovation and fresh perspective must never stop. We are innovating the complex ecosystem of drug discovery through a multidisciplinary and bold team of enthusiastic scientists. Our competencies range from computer science to medicinal chemistry, from computational biophysics to molecular biology. These are not keywords in a broader environment. Indeed, they are the building bricks of a fast-changing environment that builds new deep tech possibilities out of the arising technologies.

While we work hard to consolidate and continue to improve the existing platform, we also push forward our expectations. The medical world needs a more significant number of druggable targets and people who believe that things can change. At Sibylla, we work in this direction.


Sibylla technology can be applied to any therapeutic area.

Our internal pipeline is currently focused on oncology. The most significant impact on society is on the people suffering from debilitating or even untreatable diseases and their families.

CCND1 over-expression due to oncogenic signals promotes transformation to malignant phenotypes. It is amplified in 15% and over-expressed in 30–50% of human breast cancers, lung, breast, sarcoma, and colon cancer. CCND1 is currently undruggable.

The drug discovery industry is heavily involved in the research and experimentation of potential therapies. However, many of them are currently not resolutive and address only part of the cases. We offer an early-stage solution to the development of improved or even life-saving therapies.